Market revenue in 2021 | USD 40.7 million |
Market revenue in 2030 | USD 251.3 million |
Growth rate | 22.4% (CAGR from 2021 to 2030) |
Largest segment | Serum biomarkers |
Fastest growing segment | Hepatic Fibrosis Biomarkers |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Serum Biomarkers, Hepatic Fibrosis Biomarkers, Apoptosis Biomarkers, Oxidative Stress Biomarkers |
Key market players worldwide | Genfit SA, Siemens AG, Quest Diagnostics Inc, AstraZeneca PLC, Meridian Bioscience, Labcorp Holdings Inc, Pfizer Inc, Bristol-Myers Squibb Co |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to non-alcoholic steatohepatitis biomarkers market will help companies and investors design strategic landscapes.
Serum biomarkers was the largest segment with a revenue share of 32.92% in 2021. Horizon Databook has segmented the Canada non-alcoholic steatohepatitis biomarkers market based on serum biomarkers, hepatic fibrosis biomarkers, apoptosis biomarkers, oxidative stress biomarkers covering the revenue growth of each sub-segment from 2018 to 2030.
NAFLD is a term for a range of diseases that includes bland steatosis and NASH. About 25% of NAFLD patients develop NASH, which then progresses to liver cirrhosis and associated end-stage comorbidities. Obesity and type 2 diabetes are the main risk factors for the condition.
Dedicated to improving knowledge, care, research, and education about NAFLD with a vision of best practices for this disease condition, the Canadian NASH Network is a nationwide collaborative network of healthcare professionals and researchers.
According to an article, the prevalence of NASH is expected to be increased by 35%, reaching 2,630,000 between 2019 and 2030. Recent product launches coupled with research collaborations and favorable initiatives may support the market growth.
Horizon Databook provides a detailed overview of country-level data and insights on the Canada non-alcoholic steatohepatitis biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into Canada non-alcoholic steatohepatitis biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account